Entasis Therapeutics Holdings Inc. (NASDAQ: (ETTX) stock declined by 1.27% at last close whereas the ETTX stock price gains by 24.12% in the after-hours trading session. Entasis is a clinical-stage pharmaceutical business dedicated to the research, development, and marketing of new antibacterial medicines to cure multidrug-resistant Gram-negative bacterial infections.
ETTX stock’ Significant Update
Topline findings from Entasis Therapeutics Holdings’ ATTACK study were released. It’s a worldwide Phase 3 registrational experiment of ETTS stock that compares the efficacy and quality of SUL-DUR against colistin in patients with Acinetobacter baumannii infections. In individuals with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the trial), SUL-DUR reached the primary objective of 28-day all-cause death, exhibiting analytical non-inferiority to colistin. In CRABC m-MITT and all trial populations included in the topline results, mortality analyses supported SUL-DUR over coxlistin.
There was a substantial distinction in clinical response favoring SUL-DUR versus colistin in the Test of Cure. SUL-DUR achieved a statistically significant decrease in nephrotoxicity, which was the study’s primary safety goal.
Manos Perros, Chief Executive Officer at ETTS stock commented,
ATTACK was a ground-breaking clinical study since it was the first to effectively test an experimental agent against a drug-resistant Gram-negative bacteria. SUL-DUR is the first experimental medication to show effectiveness in a 28-day all-cause mortality study focusing on carbapenem-resistant Acinetobacter, which the CDC has classified as an “Urgent” concern. The favorable conclusion of the ATTACK trial is a significant accomplishment for Entasis and the culmination of a tremendous effort by our team. In mid-2022, they plan to meet with regulatory authorities to discuss their findings and prepare their first regulatory filing. They are thankful to their Zai Lab collaborators and investigators, as well as the patients and their families, for their involvement in this study.
Dr. Samantha Du, Chairperson, and CEO at Zai Lab stated
They are ecstatic to see the results of this first prospective, well-controlled research of CRAB-related serious infections. CRAB infections are one of the most dangerous bacterial illnesses, and there are few secure and reliable treatment options. They’re excited to offer this medication to China, where CRAB infections are still common in ICUs and cause substantial morbidity and death.
